Share Price and Basic Stock Data
Last Updated: January 29, 2026, 11:30 am
| PEG Ratio | 5.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Pharmalabs Ltd operates within the pharmaceuticals sector, with its current share price standing at ₹763 and a market capitalization of ₹6,913 Cr. The company reported a total revenue of ₹1,945 Cr for the fiscal year ending March 2023, which represented a substantial increase from ₹1,200 Cr in March 2022. However, revenue for the fiscal year ending March 2024 declined slightly to ₹1,853 Cr before rebounding to ₹2,115 Cr in March 2025. This upward trend reflects the company’s ability to adapt to market demands. Quarterly revenues also exhibit variability, with sales peaking at ₹531 Cr in September 2022 but declining to ₹440 Cr by September 2023, before showing signs of recovery in subsequent quarters. Overall, the revenue trajectory indicates resilience amid market fluctuations, highlighting Aarti Pharmalabs’ strategic positioning in a competitive landscape.
Profitability and Efficiency Metrics
The profitability metrics for Aarti Pharmalabs indicate a robust operational performance, with a reported operating profit margin (OPM) of 22.43% for the fiscal year ending March 2025, up from 18% reported in the previous fiscal year. Net profit for the same period stood at ₹272 Cr, reflecting a significant increase from ₹217 Cr in March 2024. The company recorded an interest coverage ratio (ICR) of 17.64x, highlighting its strong ability to service debt. However, the cash conversion cycle (CCC) stood at 200 days, which is relatively high compared to typical sector metrics, indicating potential inefficiencies in working capital management. Aarti Pharmalabs has also maintained a return on equity (ROE) of 14.5% and a return on capital employed (ROCE) of 17.4%, suggesting effective utilization of shareholder funds and capital for generating profits, albeit with room for improvement in operational efficiency.
Balance Sheet Strength and Financial Ratios
Aarti Pharmalabs’ balance sheet reflects a solid financial position, with total assets of ₹3,266 Cr as of September 2025, up from ₹2,906 Cr in March 2025. The company has reported reserves of ₹2,001 Cr, which provides a cushion for future investments and growth opportunities. Borrowings stood at ₹659 Cr, indicating a relatively low leverage with a total debt-to-equity ratio of 0.19. This low ratio signifies prudent financial management, allowing for growth without excessive reliance on debt. The price-to-book value ratio (P/BV) currently stands at 3.41x, higher than typical sector averages, which implies that the market has high expectations for future growth. Additionally, the current ratio of 2.01 suggests that the company is well-positioned to meet its short-term obligations, reinforcing its financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Pharmalabs showcases a diverse ownership structure, with promoters holding 42.88% of the company as of September 2025. This is a decline from 46.46% in March 2024, indicating a slight reduction in promoter confidence or potential dilution. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 8.02% and 6.95%, respectively, reflecting a moderate level of institutional interest. The public shareholding stands at 42.12%, highlighting significant retail participation. The number of shareholders has fluctuated, with a total of 1,90,655 as of September 2025, down from 2,76,664 in March 2023. This decline may suggest a consolidation phase or reduced retail interest amid market volatility. Overall, the shareholding distribution indicates a balanced confidence among promoters and institutional investors.
Outlook, Risks, and Final Insight
Looking ahead, Aarti Pharmalabs faces both opportunities and challenges. The company’s strong revenue growth and profitability metrics position it well for future expansion in the pharmaceuticals sector. However, risks include potential volatility in raw material prices and regulatory challenges that could impact margins. The relatively high cash conversion cycle raises concerns about operational efficiency that could hinder growth if not addressed. Additionally, maintaining investor confidence will be crucial, especially as promoter shareholding continues to decline. Aarti Pharmalabs must navigate these challenges while leveraging its financial strengths and market position to sustain growth. If it can enhance operational efficiencies and manage risks effectively, the company may unlock substantial value for its shareholders in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 197/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,378 Cr. | 310 | 479/192 | 70.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.7 Cr. | 45.4 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 69.6 Cr. | 47.5 | 47.6/17.0 | 166 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,348.44 Cr | 1,074.12 | 47.21 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 531 | 472 | 485 | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 |
| Expenses | 441 | 385 | 405 | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 |
| Operating Profit | 90 | 86 | 80 | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 |
| OPM % | 17% | 18% | 16% | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% |
| Other Income | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 |
| Interest | 6 | 5 | 6 | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 |
| Depreciation | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 |
| Profit before tax | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 |
| Tax % | 26% | 27% | 27% | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% |
| Net Profit | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 |
| EPS in Rs | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 |
Last Updated: December 28, 2025, 10:35 am
Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 418.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Jun 2025) to 418.00 Cr., marking an increase of 32.00 Cr..
- For Expenses, as of Sep 2025, the value is 344.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 293.00 Cr. (Jun 2025) to 344.00 Cr., marking an increase of 51.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 93.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 19.00 Cr..
- For OPM %, as of Sep 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Jun 2025) to 18.00%, marking a decrease of 6.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Jun 2025) to 11.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 65.00 Cr. (Jun 2025) to 39.00 Cr., marking a decrease of 26.00 Cr..
- For Tax %, as of Sep 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 28.00%, marking an increase of 4.00%.
- For Net Profit, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Jun 2025) to 28.00 Cr., marking a decrease of 22.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.08. The value appears to be declining and may need further review. It has decreased from 5.46 (Jun 2025) to 3.08, marking a decrease of 2.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:21 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,906 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,651 | 1,464 |
| Operating Profit | 0 | 207 | 342 | 386 | 464 | 442 |
| OPM % | 17% | 18% | 21% | 22% | 23% | |
| Other Income | 0 | 3 | 2 | 5 | 10 | 5 |
| Interest | 0 | 12 | 21 | 17 | 27 | 34 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 93 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 319 |
| Tax % | 21% | 26% | 28% | 24% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 240 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 26.45 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 58.20% | 12.44% | 25.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -45.76% | 12.91% |
Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,001 |
| Borrowings | 0 | 341 | 215 | 285 | 413 | 659 |
| Other Liabilities | 0 | 312 | 470 | 540 | 503 | 561 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,515 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 160 |
| Investments | 0 | 32 | 87 | 107 | 77 | 187 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 | 1,403 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
Below is a detailed analysis of the balance sheet data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,001.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,945.00 Cr. (Mar 2025) to 2,001.00 Cr., marking an increase of 56.00 Cr..
- For Borrowings, as of Sep 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 413.00 Cr. (Mar 2025) to 659.00 Cr., marking an increase of 246.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 561.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 561.00 Cr., marking an increase of 58.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,266.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,137.00 Cr. (Mar 2025) to 1,515.00 Cr., marking an increase of 378.00 Cr..
- For CWIP, as of Sep 2025, the value is 160.00 Cr.. The value appears to be declining and may need further review. It has decreased from 374.00 Cr. (Mar 2025) to 160.00 Cr., marking a decrease of 214.00 Cr..
- For Investments, as of Sep 2025, the value is 187.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2025) to 187.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,403.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,319.00 Cr. (Mar 2025) to 1,403.00 Cr., marking an increase of 84.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,266.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
Notably, the Reserves (2,001.00 Cr.) exceed the Borrowings (659.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -134.00 | 127.00 | 101.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 115 | 84 | 102 | 99 | |
| Inventory Days | 272 | 188 | 230 | 190 | |
| Days Payable | 123 | 106 | 135 | 90 | |
| Cash Conversion Cycle | 264 | 166 | 197 | 200 | |
| Working Capital Days | 111 | 94 | 110 | 105 | |
| ROCE % | 19% | 16% | 17% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Multi Cap Fund | 428,834 | 0.16 | 32.27 | 428,834 | 2025-04-22 15:56:51 | 0% |
| ICICI Prudential Exports and Services Fund | 100,000 | 0.52 | 7.52 | N/A | N/A | N/A |
| ICICI Prudential Childrens Fund | 93,759 | 0.5 | 7.05 | 100,000 | 2026-01-26 05:56:47 | -6.24% |
| Taurus Flexi Cap Fund | 72,058 | 1.52 | 5.42 | 59,058 | 2025-12-15 01:09:15 | 22.01% |
| HDFC Large and Mid Cap Fund | 67,500 | 0.02 | 5.08 | N/A | N/A | N/A |
| Samco Multi Cap Fund | 7,830 | 0.2 | 0.59 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 10.00 |
| Basic EPS (Rs.) | 30.06 | 23.93 | 21.35 | 13.49 |
| Diluted EPS (Rs.) | 30.04 | 23.93 | 21.35 | 13.49 |
| Cash EPS (Rs.) | 39.64 | 32.01 | 28.25 | 36.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Revenue From Operations / Share (Rs.) | 233.36 | 204.42 | 214.64 | 263.36 |
| PBDIT / Share (Rs.) | 52.35 | 43.14 | 38.00 | 45.97 |
| PBIT / Share (Rs.) | 42.76 | 35.06 | 31.10 | 36.73 |
| PBT / Share (Rs.) | 39.80 | 33.16 | 28.77 | 34.10 |
| Net Profit / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| NP After MI And SOA / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| PBDIT Margin (%) | 22.43 | 21.10 | 17.70 | 17.45 |
| PBIT Margin (%) | 18.32 | 17.14 | 14.48 | 13.94 |
| PBT Margin (%) | 17.05 | 16.21 | 13.40 | 12.94 |
| Net Profit Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| NP After MI And SOA Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| Return on Networth / Equity (%) | 13.68 | 12.34 | 12.41 | 8.81 |
| Return on Capital Employeed (%) | 17.23 | 16.83 | 17.19 | 11.46 |
| Return On Assets (%) | 9.37 | 8.40 | 8.67 | 5.99 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.15 | 0.13 | 0.24 |
| Asset Turnover Ratio (%) | 0.77 | 0.76 | 0.75 | 0.00 |
| Current Ratio (X) | 2.01 | 1.94 | 1.95 | 1.77 |
| Quick Ratio (X) | 1.12 | 1.01 | 0.93 | 0.95 |
| Inventory Turnover Ratio (X) | 3.44 | 1.38 | 1.78 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 11.64 | 8.35 | 10.04 | 2.02 |
| Dividend Payout Ratio (CP) (%) | 8.82 | 6.24 | 7.59 | 1.50 |
| Earning Retention Ratio (%) | 88.36 | 91.65 | 89.96 | 97.98 |
| Cash Earning Retention Ratio (%) | 91.18 | 93.76 | 92.41 | 98.50 |
| Interest Coverage Ratio (X) | 17.64 | 22.71 | 16.36 | 17.52 |
| Interest Coverage Ratio (Post Tax) (X) | 11.13 | 13.60 | 10.19 | 11.22 |
| Enterprise Value (Cr.) | 7172.16 | 4182.27 | 2678.01 | 0.00 |
| EV / Net Operating Revenue (X) | 3.39 | 2.26 | 1.38 | 0.00 |
| EV / EBITDA (X) | 15.12 | 10.70 | 7.78 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| Retention Ratios (%) | 88.35 | 91.64 | 89.95 | 97.97 |
| Price / BV (X) | 3.41 | 2.24 | 1.60 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| EarningsYield | 0.04 | 0.05 | 0.07 | 0.00 |
After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 30.04. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.04, marking an increase of 6.11.
- For Cash EPS (Rs.), as of Mar 25, the value is 39.64. This value is within the healthy range. It has increased from 32.01 (Mar 24) to 39.64, marking an increase of 7.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 233.36. It has increased from 204.42 (Mar 24) to 233.36, marking an increase of 28.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.35. This value is within the healthy range. It has increased from 43.14 (Mar 24) to 52.35, marking an increase of 9.21.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.76. This value is within the healthy range. It has increased from 35.06 (Mar 24) to 42.76, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 39.80. This value is within the healthy range. It has increased from 33.16 (Mar 24) to 39.80, marking an increase of 6.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For PBDIT Margin (%), as of Mar 25, the value is 22.43. This value is within the healthy range. It has increased from 21.10 (Mar 24) to 22.43, marking an increase of 1.33.
- For PBIT Margin (%), as of Mar 25, the value is 18.32. This value is within the healthy range. It has increased from 17.14 (Mar 24) to 18.32, marking an increase of 1.18.
- For PBT Margin (%), as of Mar 25, the value is 17.05. This value is within the healthy range. It has increased from 16.21 (Mar 24) to 17.05, marking an increase of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 12.87. This value exceeds the healthy maximum of 10. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.68. This value is below the healthy minimum of 15. It has increased from 12.34 (Mar 24) to 13.68, marking an increase of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.23. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 17.23, marking an increase of 0.40.
- For Return On Assets (%), as of Mar 25, the value is 9.37. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 9.37, marking an increase of 0.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.19, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has increased from 0.76 (Mar 24) to 0.77, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.01, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.12, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.44, marking an increase of 2.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.64. This value is below the healthy minimum of 20. It has increased from 8.35 (Mar 24) to 11.64, marking an increase of 3.29.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 6.24 (Mar 24) to 8.82, marking an increase of 2.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.36. This value exceeds the healthy maximum of 70. It has decreased from 91.65 (Mar 24) to 88.36, marking a decrease of 3.29.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 91.18, marking a decrease of 2.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 22.71 (Mar 24) to 17.64, marking a decrease of 5.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.13. This value is within the healthy range. It has decreased from 13.60 (Mar 24) to 11.13, marking a decrease of 2.47.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,172.16. It has increased from 4,182.27 (Mar 24) to 7,172.16, marking an increase of 2,989.89.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.26 (Mar 24) to 3.39, marking an increase of 1.13.
- For EV / EBITDA (X), as of Mar 25, the value is 15.12. This value exceeds the healthy maximum of 15. It has increased from 10.70 (Mar 24) to 15.12, marking an increase of 4.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 88.35. This value exceeds the healthy maximum of 70. It has decreased from 91.64 (Mar 24) to 88.35, marking a decrease of 3.29.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 24) to 3.41, marking an increase of 1.17.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Pharmalabs Ltd:
- Net Profit Margin: 12.87%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.68% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.5 (Industry average Stock P/E: 47.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.87%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No 22/C/1 & 22/C/2, Vapi Gujarat 396195 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant Vallabhaji Gogri | Chairman Emeritus |
| Mr. Rashesh C Gogri | Chairman & Non-Exe.Director |
| Mrs. Hetal Gogri Gala | Vice Chairperson & M.D |
| Mr. Narendra J Salvi | Managing Director |
| Mr. Rajendra V Gogri | Non Executive Director |
| Mr. Parimal H Desai | Non Executive Director |
| Ms. Nehal Garewal | Non Executive Director |
| Mr. Bhavesh R Vora | Independent Director |
| Mrs. Jeenal K Savla | Independent Director |
| Mrs. Rupal A Vora | Independent Director |
| Mr. Vilas Gajanan Gaikar | Independent Director |
| Dr. Vinay G Nayak | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
FAQ
What is the intrinsic value of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd's intrinsic value (as of 29 January 2026) is ₹793.54 which is 5.38% higher the current market price of ₹753.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹6,825 Cr. market cap, FY2025-2026 high/low of ₹972/557, reserves of ₹2,001 Cr, and liabilities of ₹3,266 Cr.
What is the Market Cap of Aarti Pharmalabs Ltd?
The Market Cap of Aarti Pharmalabs Ltd is 6,825 Cr..
What is the current Stock Price of Aarti Pharmalabs Ltd as on 29 January 2026?
The current stock price of Aarti Pharmalabs Ltd as on 29 January 2026 is ₹753.
What is the High / Low of Aarti Pharmalabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Pharmalabs Ltd stocks is ₹972/557.
What is the Stock P/E of Aarti Pharmalabs Ltd?
The Stock P/E of Aarti Pharmalabs Ltd is 28.5.
What is the Book Value of Aarti Pharmalabs Ltd?
The Book Value of Aarti Pharmalabs Ltd is 226.
What is the Dividend Yield of Aarti Pharmalabs Ltd?
The Dividend Yield of Aarti Pharmalabs Ltd is 0.67 %.
What is the ROCE of Aarti Pharmalabs Ltd?
The ROCE of Aarti Pharmalabs Ltd is 17.4 %.
What is the ROE of Aarti Pharmalabs Ltd?
The ROE of Aarti Pharmalabs Ltd is 14.5 %.
What is the Face Value of Aarti Pharmalabs Ltd?
The Face Value of Aarti Pharmalabs Ltd is 5.00.